$256 Million

Burning Rock Biotech Limited

Initial Public Offering

Bookrunner, June 2020

Burning Rock Biotech is a China-based cancer diagnostics company serving the Chinese market. The Company’s cancer therapy selection platform is built upon proprietary technologies, a comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through an in-hospital model and smaller hospitals through a central laboratory model.

More Like This

Mar 2022
$79.4 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Nov 2021
$116.3 Million

Initial Public Offering

Bookrunner

View Details
Nov 2021
$500.3 Million

Initial Public Offering

Bookrunner

View Details